Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
Author:
Funder
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Publisher
Elsevier BV
Subject
Virology,Pharmacology
Reference56 articles.
1. Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model;Abdelnabi;J. Infect. Dis.,2021
2. Protection against the omicron variant from previous SARS-CoV-2 infection;Altarawneh;N. Engl. J. Med.,2022
3. A systematic review of the global intervention for SARS-CoV-2 combating: from drugs repurposing to molnupiravir approval;Ashour;Drug Des. Dev. Ther.,2022
4. Therapeutic emergency use authorizations (EUAs) during pandemics: double-edged swords;Bhimraj;Clin. Infect. Dis.,2022
5. Modeling the binding mechanism of remdesivir, favilavir, and ribavirin to SARS-CoV-2 RNA-dependent RNA polymerase;Byléhn;ACS Cent. Sci.,2021
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. SARS-CoV-2 replication and drug discovery;Molecular and Cellular Probes;2024-10
2. COVID-19 therapeutics;Clinical Microbiology Reviews;2024-06-13
3. In vitro and in vivo validation of the antiviral effect of hCypA against SARS-CoV-2 via binding to the RBD of spike protein;Molecular Therapy;2024-06
4. Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns;Heliyon;2024-05
5. Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models;Zoological Research;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3